Correction: Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis (JAMA Psychiatry (2017) 74: 5 (493-500) DOI: 10.1001/jamapsychiatry.2017.0284);Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis

JAMA Psychiatry

Volumn 74, Issue 5, 2017, Pages 493-500

  Fusar Poli, Paolo ^a,b,c   Rutigliano, Grazia ^a,d   Stahl, Daniel ^a,c   Davies, Cathy ^a   Bonoldi, Ilaria ^a,b   Reilly, Thomas ^a   McGuire, Philip ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c and University of Bristol   (United Kingdom)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NEUROLOGICAL DIAGNOSTIC DEVICE; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RACE; RISK ASSESSMENT; RISK CALCULATOR; SEX; VALIDATION STUDY; ADOLESCENT; ENGLAND; INTERNET; MENTAL DISORDERS; MIDDLE AGED; PROCEDURES; PROGNOSIS; PSYCHOTIC DISORDERS; REGISTER; REPRODUCIBILITY; SECONDARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNET; LONDON; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; PROGNOSIS; PSYCHOTIC DISORDERS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SECONDARY CARE; YOUNG ADULT;

EID: 85018787030     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2018.1147     Document Type: Erratum

References (51)

1. Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7): 485-515.
2. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6): 1296-1306.
3. Fusar Poli P, McGorry P, Kane J. Improving outcomes of first episode psychosis. World Psychiatry. in press.
4. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303.
5. Fusar-Poli P, Cappucciati M, Rutigliano G, et al. At risk or not at risk? a meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry. 2015;14(3):322-332.
6. Braham A, Bannour AS, Ben Romdhane A, et al. Validation of the Arabic version of the Comprehensive Assessment of At Risk Mental States (CAARMS) in Tunisian adolescents and young adults. Early Interv Psychiatry. 2014;8(2): 147-154.
7. Krebs MO, Magaud E, Willard D, et al. Évaluation des états mentaux à risque de transition psychotique: validation de la version française de la CAARMS [Assessment of mental states at risk of psychotic transition: validation of the French version of the CAARMS]. Encephale. 2014;40(6): 447-456.
8. Fusar-Poli P, Schultze-Lutter F. Predictingthe onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evid Based Ment Health. 2016;19(1):10-15.
9. Fusar-Poli P, Bechdolf A, Taylor MJ, et al. At risk for schizophrenic or affective psychoses? a meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull. 2013; 39(4):923-932.
10. Webb JR, Addington J, Perkins DO, et al. Specificity of incident diagnostic outcomes in patients at clinical high risk for psychosis. Schizophr Bull. 2015;41(5):1066-1075.
11. Fusar-Poli P, Rutigliano G, Stahl D, et al. Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. Eur Psychiatry. 2016;42:49-54.
12. Kempton MJ, Bonoldi I, Valmaggia L, McGuire P, Fusar-Poli P. Speed of psychosis progression in people at ultra-high clinical risk: a complementary meta-analysis. JAMA Psychiatry. 2015;72(6):622-623.
13. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346:f185.
14. Deas G, Kelly C, Hadjinicolaou AV, Holt C, Agius M, Zaman R. An update on: meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at risk mental states. Psychiatr Danub. 2016;28(suppl1): 31-38.
15. NICE. Psychosis and schizophrenia in children and young people: recognition and management. http://www.nice.org.uk/Guidance/CG155. Published 2013. Accessed January 17, 2016.
16. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40(1):120-131.
17. Conrad AM, Lewin TJ, Sly KA, et al. Utility of risk-status for predicting psychosis and related outcomes: evaluation of a 10-year cohort of presenters to a specialised early psychosis community mental health service. Psychiatry Res. 2017;247:336-344.
18. Van Os J, Murray RM. Can we identify and treat "schizophrenia light" to prevent true psychotic illness? BMJ. 2013;346:f304
19. Stewart R, Soremekun M, Perera G, et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry. 2009;9:51.
20. Studerus E, Ramyead A, Riecher-Rössler A. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychol Med. 2017; 1-16.
21. Benchimol EI, Smeeth L, Guttmann A, et al; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoSMed. 2015;12(10):e1001885.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
23. Greenwood M. The Natural Duration of Cancer. London, England: Her Majesty's Stationery Office; 1926.
24. Kirkbride JB, Jackson D, Perez J, et al. A population-level prediction tool for the incidence of first-episode psychosis: translational epidemiology based on cross-sectional data. BMJ Open. 2013;3(2):e001998.
25. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.
26. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138.
27. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63.
28. Grambsch P, Therneau T Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:(3)515-526. doi:10.1093/biomet/81.3.515
29. Perera G, Broadbent M, Callard F, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource. BMJ Open. 2016;6 (3):e008721.
30. Machin D, Cheung Y, Parmar M. Survival Analysis: A Practical Approach. 2nd ed. Chichester, England: John Wiley and Sons Ltd; 2006.
31. Royston P. Explained variation for survival models. Stata J. 2006;6(1):83-96.
32. Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25(4):1692-1706.
33. Harrell F. Regression modeling strategies. http://biostat.mc.vanderbilt.edu/rms. Published 2017. Accessed January 13, 2017
34. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214-226.
35. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostictests. BMJ. 2016;352:i6.
36. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostictests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.
37. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS One. 2013;8(12):e82365.
38. Francesconi M, Minichino A, Carrión RE, et al. Psychosis prediction in secondary mental health services: a broad, comprehensive approach to the "at risk mental state" syndrome. Eur Psychiatry. 2016;40:96-104
39. Fusar-Poli P, Cappucciati M, DeMicheli A, et al. Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in individuals at ultra high risk. Schizophr Bull. 2017; 43(1):48-56.
40. Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMAPsychiatry. 2016;73(3):211-220.
41. Fusar-Poli P, Cappucciati M, Borgwardt S, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry. 2016;73(2):113-120.
42. Fusar-Poli P, Byrne M, Badger S, Valmaggia LR, McGuire PK. Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. Eur Psychiatry. 2013;28(5):315-326.
43. Schultze-Lutter F, Michel C, Schmidt SJ, et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3): 405-416.
44. Fusar-Poli P, Rutigliano G, Stahl D, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016;73(12):1260-1267
45. Valmaggia LR, Byrne M, Day F, et al. Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. Br J Psychiatry. 2015;207(2): 130-134
46. Woodberry KA, Seidman LJ, Bryant C, et al. Treatment precedes positive symptoms in north american adolescent and young adult clinical high risk cohort. J Clin Child Adolesc Psychol. 2016;1-10.
47. Carrión RE, Correll CU, Auther AM, Cornblatt BA. A severity-based clinical staging model for the psychosis prodrome: longitudinal findings from the new york recognition and prevention program. Schizophr Bull. 2017;43(1):64-74
48. Addington J, Liu L, Perkins DO, Carrion RE, Keefe RS, Woods SW. The role of cognition and social functioning as predictors in the transition to psychosis for youth with attenuated psychotic symptoms. Schizophr Bull. 2017;43(1):57-63.
49. Schmidt A, Cappucciati M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophr Bull. 2016;sbw098.
50. Clark SR, Baune BT, Schubert KO, et al. Prediction of transition from ultra-high riskto first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers. Transl Psychiatry. 2016;6(9):e897.
51. Scott J, Marwaha S, Ratheesh A, et al. Bipolar at-risk criteria: an examination of which clinical features have optimal utility for identifying youth at risk of early transition from depression to bipolar disorders. Schizophr Bull. 2016;sbw154.